Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Amides chemistry MeSH
- Antibiotics, Antineoplastic pharmacology MeSH
- Leukosialin metabolism MeSH
- Apoptosis MeSH
- Doxorubicin analogs & derivatives pharmacology MeSH
- Endoplasmic Reticulum metabolism MeSH
- Galectin 1 metabolism MeSH
- Glycosylation MeSH
- Golgi Apparatus metabolism MeSH
- Polymethacrylic Acids pharmacology MeSH
- Lymphoma, T-Cell drug therapy metabolism pathology MeSH
- Mice MeSH
- Cell Line, Tumor drug effects MeSH
- Drug Carriers MeSH
- Cell Proliferation MeSH
- Flow Cytometry MeSH
- Blotting, Western MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Amides MeSH
- Antibiotics, Antineoplastic MeSH
- Leukosialin MeSH
- doxorubicin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate MeSH Browser
- Doxorubicin MeSH
- Galectin 1 MeSH
- Polymethacrylic Acids MeSH
- Drug Carriers MeSH
To avoid the side effects of the anti-cancer drug doxorubicin (Dox), we conjugated this drug to a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone. Dox was conjugated via an amide bond (Dox-HPMA(AM), PK1) or a hydrazone pH-sensitive bond (Dox-HPMA(HYD)). In contrast to Dox and Dox-HPMA(HYD), Dox-HPMA(AM) accumulates within the cell's intracellular membranes, including those of the Golgi complex and endoplasmic reticulum, both involved in protein glycosylation. Flow cytometry was used to determine lectin binding and cell death, immunoblot to characterize the presence of CD7, CD43, CD44, and CD45, and high-performance anion exchange chromatography with pulsed amperometric detector analysis for characterization of plasma membrane saccharide composition. Incubation of EL4 cells with Dox-HPMA(AM) conjugate, in contrast to Dox or Dox-HPMA(HYD), increased the amounts of membrane surface-associated glycoproteins, as well as saccharide moieties recognized by peanut agglutinin, Erythrina cristagalli, or galectin-1 lectins. Only Dox-HPMA(AM) increased expression of the highly glycosylated membrane glycoprotein CD43, while expression of others (CD7, CD44, and CD45) was unaffected. The binding sites for galectin-1 are present on CD43 molecule. Furthermore, we present that EL4 treated with Dox-HPMA(AM) possesses increased sensitivity to galectin-1-induced apoptosis. In this study, we demonstrate that Dox-HPMA(AM) treatment changes glycosylation of the EL4 T cell lymphoma surface and sensitizes the cells to galectin-1-induced apoptosis.
See more in PubMed
J Control Release. 2001 May 18;73(1):89-102 PubMed
Bioconjug Chem. 2000 Sep-Oct;11(5):664-73 PubMed
Bioessays. 2005 Jan;27(1):50-6 PubMed
Pharm Res. 1999 Jul;16(7):986-96 PubMed
Expert Opin Biol Ther. 2008 Jan;8(1):45-57 PubMed
Biochim Biophys Acta. 2008 Mar;1780(3):325-46 PubMed
Glycoconj J. 1998 Aug;15(8):737-47 PubMed
J Control Release. 2005 Dec 10;110(1):119-29 PubMed
J Exp Med. 1996 Aug 1;184(2):759-64 PubMed
J Immunol. 1999 Oct 1;163(7):3801-11 PubMed
J Control Release. 2004 Sep 30;99(2):301-14 PubMed
J Biol Chem. 1986 Aug 5;261(22):10119-26 PubMed
Cancer Cell. 2004 Mar;5(3):241-51 PubMed
Anal Biochem. 1988 Apr;170(1):54-62 PubMed
Folia Microbiol (Praha). 1997;42(3):277-87 PubMed
Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 PubMed
J Control Release. 2003 Aug 28;91(1-2):1-16 PubMed
Trends Biotechnol. 2009 Jan;27(1):11-7 PubMed
Biochem Biophys Res Commun. 2008 May 23;370(1):149-53 PubMed
J Control Release. 2002 Apr 23;80(1-3):101-17 PubMed
J Clin Oncol. 2005 Dec 10;23(35):8932-41 PubMed
Scand J Immunol. 2005 Jul;62 Suppl 1:100-5 PubMed
J Immunol. 2006 Oct 15;177(8):5328-36 PubMed
J Control Release. 2000 Feb 14;64(1-3):63-79 PubMed
J Drug Target. 2006 Jul;14(6):391-403 PubMed
Bioconjug Chem. 2007 May-Jun;18(3):894-902 PubMed
Pharmacol Rev. 2004 Jun;56(2):185-229 PubMed
Hum Exp Toxicol. 2001 Sep;20(9):461-70 PubMed
J Control Release. 2008 Apr 21;127(2):110-20 PubMed
Anal Biochem. 1994 Jun;219(2):375-8 PubMed
J Biol Chem. 2005 Feb 18;280(7):5549-62 PubMed
Adv Enzyme Regul. 2001;41:189-207 PubMed
Adv Drug Deliv Rev. 2002 Sep 13;54(5):653-74 PubMed
Nature. 1995 Dec 14;378(6558):736-9 PubMed
J Immunol. 2000 Sep 1;165(5):2331-4 PubMed
Biomaterials. 1989 Jul;10(5):335-42 PubMed
Clin Cancer Res. 1999 Jan;5(1):83-94 PubMed
Cancer Immunol Immunother. 2007 Jan;56(1):35-47 PubMed
